Paclitaxel-coated balloons for vulnerable lipid-rich plaques.
作者信息
van Veelen Anna, Küçük I Tarik, Garcia-Garcia Hector M, Fuentes Federico H, Kahsay Yirga, Delewi Ronak, Beijk Marcel A M, den Hartog Alexander W, Grundeken Maik J, Vis M Marije, Henriques José P S, Claessen Bimmer E P M
机构信息
Department of Cardiology, Heart Center, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
Department of Cardiology, MedStar Washington Hospital Center, Washington, D.C., USA.
出版信息
EuroIntervention. 2024 Jul 1;20(13):e826-e830. doi: 10.4244/EIJ-D-23-01073.
Abstract
摘要
相似文献
1
Paclitaxel-coated balloons for vulnerable lipid-rich plaques.用于富含脂质易损斑块的紫杉醇涂层球囊。
EuroIntervention. 2024 Jul 1;20(13):e826-e830. doi: 10.4244/EIJ-D-23-01073.
2
Long-Term Results of Drug-Coated Balloons for Drug-Eluting In-Stent Restenosis: Gaining Perspective.药物涂层球囊治疗药物洗脱支架内再狭窄的长期结果：深入剖析
JACC Cardiovasc Interv. 2015 Jun;8(7):885-8. doi: 10.1016/j.jcin.2015.02.013. Epub 2015 May 20.
3
A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels.一项关于紫杉醇涂层球囊与依维莫司洗脱支架治疗小冠状动脉血管的倾向评分匹配比较研究。
Catheter Cardiovasc Interv. 2017 Sep 1;90(3):380-386. doi: 10.1002/ccd.26929. Epub 2017 Jan 21.
4
Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).紫杉醇涂层球囊与球囊血管成形术治疗的长期结果：PEPCAD-DES 研究的见解（使用 SeQuent Please 紫杉醇涂层经皮腔内冠状动脉血管成形术 [PTCA] 导管治疗药物洗脱支架 [DES] 支架内再狭窄）。
JACC Cardiovasc Interv. 2015 Nov;8(13):1695-700. doi: 10.1016/j.jcin.2015.07.023.
5
Biolimus-coated versus paclitaxel-coated balloons for coronary in-stent restenosis (BIO ASCEND ISR): a randomised, non-inferiority trial.载比伐卢定涂层球囊与紫杉醇涂层球囊治疗冠状动脉支架内再狭窄（BIO ASCEND ISR）：一项随机、非劣效性试验。
EuroIntervention. 2024 Jul 1;20(13):e806-e817. doi: 10.4244/EIJ-D-24-00295.
6
Reply: Biological differences of three paclitaxel- and sirolimus-coated balloons on coronary lesions in a rabbit model.回复：三种紫杉醇和西罗莫司涂层球囊对兔冠状动脉病变的生物学差异
EuroIntervention. 2024 Aug 5;20(15):e955-e956. doi: 10.4244/EIJ-D-24-00476.
7
Predictors of late lumen enlargement after drug-coated balloon angioplasty for de novo coronary lesions.药物涂层球囊血管成形术后新发冠状动脉病变晚期管腔扩大的预测因素。
EuroIntervention. 2024 May 10;20(9):602-612. doi: 10.4244/EIJ-D-23-00849.
8
Letter: Biological differences of three paclitaxel- and sirolimus-coated balloons on coronary lesions in a rabbit model.信函：三种紫杉醇和西罗莫司涂层球囊对兔冠状动脉病变的生物学差异
EuroIntervention. 2024 Aug 5;20(15):e954. doi: 10.4244/EIJ-D-24-00423.
9
A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions.随机试验：西罗莫司与紫杉醇涂层球囊治疗初发冠状动脉病变的比较
EuroIntervention. 2024 Nov 4;20(21):e1322-e1329. doi: 10.4244/EIJ-D-23-00868.
10
Risk of Mortality with Paclitaxel Drug-Coated Balloon in De Novo Coronary Artery Disease.紫杉醇药物涂层球囊用于初发冠状动脉疾病的死亡风险
Cardiovasc Revasc Med. 2020 Apr;21(4):549-555. doi: 10.1016/j.carrev.2020.01.012. Epub 2020 Jan 16.
引用本文的文献
1
Advances in the Detection and Management of Vulnerable Coronary Plaques.易损冠状动脉斑块的检测与管理进展
Circ Cardiovasc Interv. 2025 Aug;18(8):e015529. doi: 10.1161/CIRCINTERVENTIONS.125.015529. Epub 2025 Jul 28.
2
Drug-Coated Balloon PCI in Different Plaque Morphologies: A Narrative Review.不同斑块形态下的药物涂层球囊经皮冠状动脉介入治疗：一项叙述性综述
Biomedicines. 2025 Jun 14;13(6):1472. doi: 10.3390/biomedicines13061472.
3
[Debate: Preventive coronary intervention for vulnerable plaque. The interventional cardiologist's approach].[辩论：易损斑块的预防性冠状动脉介入治疗。介入心脏病学家的方法]
REC Interv Cardiol. 2024 Oct 16;7(1):54-56. doi: 10.24875/RECIC.M24000485. eCollection 2025 Jan-Mar.
4
Management of Coronary Vulnerable Plaques: A Focus on Preventive Percutaneous Coronary Intervention.冠状动脉易损斑块的管理：聚焦预防性经皮冠状动脉介入治疗
Rev Cardiovasc Med. 2025 Apr 17;26(4):26712. doi: 10.31083/RCM26712. eCollection 2025 Apr.
5
Expanding the Role of Drug-Coated Balloons in Treating De Novo Coronary Artery Disease.扩大药物涂层球囊在治疗初发冠状动脉疾病中的作用。
JACC Asia. 2025 Jan 7;5(1):25-27. doi: 10.1016/j.jacasi.2024.11.021. eCollection 2025 Jan.
6
Computed Tomography Angiography Identified High-Risk Coronary Plaques: From Diagnosis to Prognosis and Future Management.计算机断层扫描血管造影术识别出的高危冠状动脉斑块：从诊断到预后及未来管理
Diagnostics (Basel). 2024 Aug 1;14(15):1671. doi: 10.3390/diagnostics14151671.
本文引用的文献
1
First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study.首例人体药物洗脱球囊治疗易损富脂斑块：DEBuT-LRP研究的原理与设计
J Clin Med. 2023 Sep 6;12(18):5807. doi: 10.3390/jcm12185807.
2
Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States.2005 年至 2018 年期间，美国 239234 例急性冠脉综合征患者的心血管事件复发率和死亡率的事件发生率及危险因素分析。
J Am Heart Assoc. 2022 May 3;11(9):e022198. doi: 10.1161/JAHA.121.022198. Epub 2022 Apr 27.
3
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.经冠状动脉近红外光谱和超声（PROSPECT II）识别易损斑块和患者：一项前瞻性自然史研究。
Lancet. 2021 Mar 13;397(10278):985-995. doi: 10.1016/S0140-6736(21)00249-X.
4
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque.经皮冠状动脉介入治疗易损冠状动脉粥样硬化斑块
J Am Coll Cardiol. 2020 Nov 17;76(20):2289-2301. doi: 10.1016/j.jacc.2020.09.547. Epub 2020 Oct 15.
5
Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits.紫杉醇药物涂层球囊血管成形术抑制兔实验性动脉粥样硬化的进展和炎症。
JACC Basic Transl Sci. 2020 Jun 10;5(7):685-695. doi: 10.1016/j.jacbts.2020.04.007. eCollection 2020 Jul.
6
A prospective natural-history study of coronary atherosclerosis.前瞻性冠状动脉粥样硬化的自然病史研究。
N Engl J Med. 2011 Jan 20;364(3):226-35. doi: 10.1056/NEJMoa1002358.
Zotero 插件